DK1624871T3 - Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger - Google Patents

Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger

Info

Publication number
DK1624871T3
DK1624871T3 DK04785539T DK04785539T DK1624871T3 DK 1624871 T3 DK1624871 T3 DK 1624871T3 DK 04785539 T DK04785539 T DK 04785539T DK 04785539 T DK04785539 T DK 04785539T DK 1624871 T3 DK1624871 T3 DK 1624871T3
Authority
DK
Denmark
Prior art keywords
dyslipidemia
pharmaceutical compositions
related conditions
treating atherosclerosis
atherosclerosis
Prior art date
Application number
DK04785539T
Other languages
English (en)
Inventor
Kang Cheng
M Gerard Waters
Kathleen M Metters
Gary O'neill
Original Assignee
Merck & Co Inc
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1624871(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc, Merck Frosst Canada Ltd filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1624871T3 publication Critical patent/DK1624871T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
DK04785539T 2003-05-15 2004-05-13 Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger DK1624871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15
PCT/US2004/014980 WO2004103370A1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK1624871T3 true DK1624871T3 (da) 2009-11-16

Family

ID=33476734

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04785539T DK1624871T3 (da) 2003-05-15 2004-05-13 Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
DK09163448.5T DK2116244T3 (da) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09163448.5T DK2116244T3 (da) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions

Country Status (45)

Country Link
US (4) US20040229844A1 (da)
EP (3) EP2116244B1 (da)
JP (2) JP4637833B2 (da)
KR (2) KR100806008B1 (da)
CN (3) CN100441184C (da)
AR (1) AR041089A1 (da)
AU (2) AU2004240597B2 (da)
BR (1) BRPI0410273A (da)
CA (1) CA2525772C (da)
CL (1) CL2004001056A1 (da)
CO (1) CO5630034A2 (da)
CR (2) CR8047A (da)
CY (2) CY1109476T1 (da)
DE (1) DE602004022036D1 (da)
DK (2) DK1624871T3 (da)
DO (1) DOP2004000907A (da)
EA (2) EA009744B1 (da)
EC (1) ECSP056156A (da)
ES (2) ES2328148T3 (da)
GE (2) GEP20084569B (da)
GT (1) GT200400098A (da)
HK (1) HK1092722A1 (da)
HN (1) HN2004000171A (da)
HR (2) HRP20090424T1 (da)
IL (1) IL171962A (da)
IS (1) IS2708B (da)
JO (1) JO2564B1 (da)
MA (1) MA27835A1 (da)
ME (1) MEP60108A (da)
MX (1) MXPA05012272A (da)
MY (1) MY140639A (da)
NO (1) NO20055957L (da)
NZ (2) NZ572515A (da)
PA (1) PA8603201A1 (da)
PE (1) PE20050552A1 (da)
PL (2) PL2116244T3 (da)
PT (2) PT1624871E (da)
RS (3) RS20120499A1 (da)
SG (1) SG153667A1 (da)
SI (2) SI1624871T1 (da)
TN (1) TNSN05290A1 (da)
TW (2) TWI334354B (da)
UA (1) UA89615C2 (da)
WO (1) WO2004103370A1 (da)
ZA (1) ZA200508288B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272712T3 (es) * 2001-05-23 2007-05-01 Merck Frosst Canada Ltd. Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2.
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
PL2801354T3 (pl) 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006078776A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
AU2006214018A1 (en) * 2005-02-17 2006-08-24 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
WO2006124490A2 (en) * 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2620570A1 (en) * 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
KR20080091814A (ko) * 2006-01-20 2008-10-14 쉐링 코포레이션 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
CA2663434A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
CA2663503A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
NZ589469A (en) * 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP3295936A1 (en) 2009-01-09 2018-03-21 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
JP2013522306A (ja) 2010-03-16 2013-06-13 アベンティス・ファーマスーティカルズ・インコーポレイテツド プロスタグランジンｄ２受容体アンタゴニストとしての置換ピリミジン類
WO2011115943A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2857653A1 (de) 1977-09-30 1981-02-05 Rca Corp Einrichtung in einem fernsehsystem
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
NZ321766A (en) 1995-10-31 1999-07-29 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
CZ288545B6 (cs) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
CA2298549C (en) * 1997-07-31 2006-01-10 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
BR9812770A (pt) * 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CA2353981C (en) 1998-12-07 2005-04-26 Schering Corporation Process for the synthesis of azetidinones
NZ512532A (en) 1998-12-23 2003-12-19 G Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis
CA2367289C (en) 1999-04-05 2008-02-12 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
JP4292742B2 (ja) 2000-03-09 2009-07-08 小野薬品工業株式会社 インドール誘導体、その製造方法および用途
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
WO2002084298A2 (en) 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
ES2272712T3 (es) * 2001-05-23 2007-05-01 Merck Frosst Canada Ltd. Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2.
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
RU2329256C2 (ru) 2002-03-19 2008-07-20 Оно Фармасьютикал Ко., Лтд. Производное карбоновой кислоты, фармацевтическая композиция и средство для профилактики и/или лечения заболеваний, вызванных активацией dp-рецептора, применение производного карбоновой кислоты для производства такого средства, способ профилактики и/или лечения заболеваний, вызываемых активацией dp-рецепторов
CN100402026C (zh) * 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
EA200702674A1 (ru) 2008-04-28
CA2525772C (en) 2011-03-15
TWI341199B (en) 2011-05-01
AU2011200986B2 (en) 2012-11-08
DE602004022036D1 (de) 2009-08-27
KR100960749B1 (ko) 2010-06-01
CN102526735A (zh) 2012-07-04
NO20055957L (no) 2006-02-14
AU2004240597A1 (en) 2004-12-02
IL171962A0 (en) 2006-04-10
MY140639A (en) 2010-01-15
RS20120499A1 (en) 2013-08-30
KR20060012617A (ko) 2006-02-08
IL171962A (en) 2012-06-28
CR9808A (es) 2008-07-29
RS52731B (sr) 2013-08-30
TW200503757A (en) 2005-02-01
GEP20084569B (en) 2008-12-25
AR041089A1 (es) 2005-05-04
MXPA05012272A (es) 2006-05-19
PL1624871T3 (pl) 2009-12-31
PA8603201A1 (es) 2005-02-04
CY1109476T1 (el) 2014-08-13
GEP20105025B (en) 2010-06-25
EP1624871B1 (en) 2009-07-15
CR8047A (es) 2006-07-14
KR100806008B1 (ko) 2008-02-26
DOP2004000907A (es) 2004-11-30
KR20080003470A (ko) 2008-01-07
SG153667A1 (en) 2009-07-29
RS20050777A (sr) 2008-04-04
CN100441184C (zh) 2008-12-10
NZ543399A (en) 2009-02-28
EA009744B1 (ru) 2008-04-28
TWI334354B (en) 2010-12-11
PL2116244T3 (pl) 2013-01-31
HRP20090424T1 (en) 2009-09-30
AU2011200986A1 (en) 2011-03-31
JO2564B1 (en) 2010-11-03
JP4637833B2 (ja) 2011-02-23
CY1113342T1 (el) 2016-06-22
TNSN05290A1 (en) 2007-07-10
CO5630034A2 (es) 2006-04-28
CL2004001056A1 (es) 2005-03-28
IS8071A (is) 2005-10-13
US20110118292A1 (en) 2011-05-19
EP2116244B1 (en) 2012-08-08
SI1624871T1 (sl) 2009-12-31
US20090233977A1 (en) 2009-09-17
HN2004000171A (es) 2011-07-11
SI2116244T1 (sl) 2012-12-31
IS2708B (is) 2011-01-15
EP1624871A1 (en) 2006-02-15
CN101559227B (zh) 2012-03-21
EA011895B1 (ru) 2009-06-30
EP2286816A1 (en) 2011-02-23
AU2004240597B2 (en) 2011-01-06
ES2328148T3 (es) 2009-11-10
PT1624871E (pt) 2009-09-07
PT2116244E (pt) 2012-11-02
CN1787819A (zh) 2006-06-14
WO2004103370A1 (en) 2004-12-02
MEP60108A (en) 2011-05-10
US20040229844A1 (en) 2004-11-18
ECSP056156A (es) 2006-04-19
DK2116244T3 (da) 2012-11-26
UA89615C2 (ru) 2010-02-25
EP2116244A1 (en) 2009-11-11
EA200501817A1 (ru) 2006-06-30
JP2006526030A (ja) 2006-11-16
NZ572515A (en) 2010-07-30
HRP20120818T1 (hr) 2012-11-30
JP2010077151A (ja) 2010-04-08
BRPI0410273A (pt) 2006-05-16
ZA200508288B (en) 2008-08-27
CN101559227A (zh) 2009-10-21
PE20050552A1 (es) 2005-08-06
RS20120498A1 (en) 2013-08-30
ES2392743T3 (es) 2012-12-13
GT200400098A (es) 2005-03-03
CA2525772A1 (en) 2004-12-02
MA27835A1 (fr) 2006-04-03
HK1092722A1 (en) 2007-02-16
TW200803844A (en) 2008-01-16
US20100076002A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
DK1624871T3 (da) Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1862158T3 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
DK1891571T3 (da) Hæmning af spredning af uønskede koder og data
NO20052547D0 (no) System og fremgangsmate for foretrukken applikasjonsinstallasjon og -eksekvering.
DK1874557T3 (da) Identitetsdokument og fremgangsmåde til fremstilling deraf
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1791791T3 (da) Fremgangsmåder og sammensætninger til behandling af vand
DK1499184T3 (da) Sammensætninger til behandling af ektoparasitangreb
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
DK1550535T3 (da) Fremgangsmåde og indretning til fremstilling af betonmasse
DK3159357T3 (da) Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
DK2037936T3 (da) Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
DK1883293T3 (da) Sammensætning og fremgangsmåde til kontrol af insekter
DK1673214T3 (da) Apparat og fremgangsmåde til behandling af slam
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
DK1786680T3 (da) Beskyttet hætteglas og fremgangsmåde til fremstilling heraf
DK1596868T3 (da) Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1461047T3 (da) Sammensætninger og fremgangsmåde til behandling af dyr
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK1768489T3 (da) Apparat og fremgangsmåde til destruktion af vegetation